Perspective Therapeutics (NYSEAMERICAN:CATX) Director Buys $12,000.00 in Stock

Perspective Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Director Robert Williamson III bought 15,000 shares for $12,000 at $0.80 per share, increasing his stake by 28.05% to 68,473 shares.
  • Perspective Therapeutics shares fell 9.3% and opened at $0.78, matching their 12-month low of $0.78.
  • The company missed quarterly estimates, reporting a loss of $0.27 per share versus the $0.24 loss analysts expected, and revenue of $0.02 million versus $0.06 million expected.
  • Five stocks to consider instead of Perspective Therapeutics.

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) Director Robert Williamson III purchased 15,000 shares of the business's stock in a transaction dated Wednesday, November 18th. The shares were purchased at an average cost of $0.80 per share, with a total value of $12,000.00. Following the purchase, the director directly owned 68,473 shares in the company, valued at approximately $54,778.40. The trade was a 28.05% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Perspective Therapeutics Trading Down 9.3%

NYSEAMERICAN:CATX opened at $0.78 on Thursday. Perspective Therapeutics, Inc. has a twelve month low of $0.78 and a twelve month high of $6.16. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.18 and a current ratio of 5.18. The company has a 50-day moving average of $1.98 and a 200-day moving average of $3.40.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.06 million. Perspective Therapeutics had a negative net margin of 55,866.82% and a negative return on equity of 42.25%. Equities analysts expect that Perspective Therapeutics, Inc. will post -1.01 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Wedbush reissued an "outperform" rating and set a $7.00 target price (down from $9.00) on shares of Perspective Therapeutics in a research note on Tuesday, November 10th. Bank of America dropped their price objective on shares of Perspective Therapeutics from $6.00 to $5.00 and set a "neutral" rating for the company in a research report on Friday, August 14th. Royal Bank Of Canada lowered Perspective Therapeutics from an "outperform" rating to a "sector perform" rating and reduced their price objective for the stock from $14.00 to $4.00 in a research note on Monday, October 26th. William Blair started coverage on shares of Perspective Therapeutics in a report on Friday, September 18th. They set an "outperform" rating for the company. Finally, Piper Sandler cut their price target on Perspective Therapeutics from $16.00 to $14.00 and set an "overweight" rating for the company in a research note on Tuesday, August 11th. Nine equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Perspective Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $10.10.

View Our Latest Stock Analysis on Perspective Therapeutics

Institutional Investors Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CATX. Commodore Capital LP purchased a new stake in shares of Perspective Therapeutics during the first quarter worth about $26,424,000. Affinity Asset Advisors LLC boosted its position in Perspective Therapeutics by 954.9% during the 1st quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company's stock worth $13,196,000 after acquiring an additional 2,864,582 shares during the period. Avidity Partners Management LP raised its holdings in Perspective Therapeutics by 88.4% during the first quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company's stock valued at $25,228,000 after buying an additional 2,839,266 shares in the last quarter. Spruce Street Capital LP bought a new position in shares of Perspective Therapeutics during the 1st quarter worth about $10,955,000. Finally, Marshall Wace LLP acquired a new stake in Perspective Therapeutics during the 3rd quarter worth $4,075,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

(Get Free Report)

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company's investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.

Further Reading

Insider Buying and Selling by Quarter for Perspective Therapeutics (NYSEAMERICAN:CATX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Perspective Therapeutics Right Now?

Before you consider Perspective Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Perspective Therapeutics wasn't on the list.

While Perspective Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines